7 news items
Nurix Therapeutics Announces Board Chair Transition
NRIX
20 May 24
and strategic vision will be invaluable as we accelerate development of our drug programs towards regulatory approval and commercialization with the goal
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
NRIX
9 Apr 24
and results of clinical trials; (iv) whether Nurix will be able to fund its research and development activities and achieve its research and development goals
Nurix Therapeutics Extends Ongoing Research Program With Sanofi For STAT6; Anticipates Nominating A Clinical Candidate Within The First Year Of Extension
NRIX
SNY
9 Apr 24
. With today's announcement, Nurix and Sanofi have agreed to extend the research term for the ongoing STAT6 program with the goal of nominating a development candidate in the first year of the extended term.
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
NRIX
2 Apr 24
and achieve development goals, including those under the Nurix-Gilead collaboration; (v) risks and uncertainties relating to the timing and receipt
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
NRIX
25 Mar 24
Childhood Cancers" (KOODAC) has the goal of developing orally bioavailable targeted protein degraders that have the potential to dramatically improve
mrocroafhzvb3 ogm9o0506myi2iuyxs
NRIX
20 Mar 24
during clinical development; (iii) whether Nurix will be able to fund development activities and achieve development goals; (iv) risks
9in3aeb 8mbx7v9dvwsiaaj
NRIX
11 Mar 24
will be able to fund development activities and achieve development goals; (v) the impact of economic and market conditions and global and regional events
- Prev
- 1
- Next